KK
RXRX icon

KLP Kapitalforvaltning’s Recursion Pharmaceuticals RXRX Stock Holding History

KLP Kapitalforvaltning’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Hold
97,500
– – ﹤0.01% 1656
2026
Q1 		$299K Buy
97,500
+19,300
+25% +$74.6K ﹤0.01% 1666
2025
Q4 		$320K Buy
78,200
+5,200
+7% +$25.8K ﹤0.01% 1636
2025
Q3 		$356K Buy
73,000
+11,800
+19% +$62K ﹤0.01% 1571
2025
Q2 		$310K Buy
61,200
+10,000
+20% +$49.1K ﹤0.01% 1592
2025
Q1 		$271K Hold
51,200
– – ﹤0.01% 1609
2024
Q4 		$346K Buy
+51,200
New +$344K ﹤0.01% 1568

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

KLP Kapitalforvaltning's RXRX Position: Q2 2026 in Review

KLP Kapitalforvaltning held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 97,500 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

KLP Kapitalforvaltning first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • KLP Kapitalforvaltning held 97,500 shares of Recursion Pharmaceuticals worth $358K as of Q2 2026.
  • KLP Kapitalforvaltning left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1656 holding.
  • KLP Kapitalforvaltning first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.